Improved access to a cancer genetics service could dramatically reduce mortality in Irish women with an inherited predisposition to breast and ovarian cancer. Gynecologist and geneticist Noah Kauff is mentioned.
An experimental surgical procedure offers hope of a cure for one of the most dreaded side effects of breast cancer treatment — the arm pain that’s often caused by removing lymph nodes. Plastic surgeon Babak Mehrara is quoted.
The Today Show celebrated with several patients at the 2011 MSKCC Pediatric Convocation celebration. Two Memorial Sloan-Kettering Cancer Center patients were profiled and pediatric oncologist Richard O’Reilly was interviewed.
The past century has seen great strides in the treatment of retinoblastoma, with more than 95 percent of US patients now being cured of this rare childhood malignancy. Ophthalmic oncologist David Abramson is quoted.
While most patients with advanced lung cancer take four courses of two chemotherapy drugs and then stop until recurrence occurs, continuing treatment with one of those drugs may delay return of the disease. Medical oncologist Mark Kris is quoted.
A phase III trial showed that flaxseed did not significantly reduce hot flashes in postmenopausal women with or without breast cancer. Medical oncologist Mark Kris is quoted.
A study led by gynecologic oncologist Carol Aghajanian showed the drug bevacizumab (Avastin®) delayed the progression of advanced ovarian cancer. She is quoted in the article.
According to research led by investigators at Memorial Sloan-Kettering Cancer Center, two new drugs — vemurafenib and ipilimumab (Yervoy™) — were found to prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer. Medical oncologist Paul Chapman and Jedd Wolchok (vemurafenib )are quoted.
According to research led by investigators at Memorial Sloan-Kettering Cancer Center, two new drugs — vemurafenib and ipilimumab (Yervoy™) — were found to prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer. Medical oncologist Paul Chapman and Jedd Wolchok (vemurafenib )are quoted.
According to research led by investigators at Memorial Sloan-Kettering Cancer Center, two new drugs — vemurafenib and ipilimumab (Yervoy™) — were found to prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer. Medical oncologist Paul Chapman and Jedd Wolchok (vemurafenib )are quoted.
According to research led by investigators at Memorial Sloan-Kettering Cancer Center, two new drugs — vemurafenib and ipilimumab (Yervoy™) — were found to prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer. Medical oncologist Paul Chapman and Jedd Wolchok (vemurafenib )are quoted.
According to research led by investigators at Memorial Sloan-Kettering Cancer Center, two new drugs — vemurafenib and ipilimumab (Yervoy™) — were found to prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer. Medical oncologist Paul Chapman and Jedd Wolchok (vemurafenib )are quoted.
According to research led by investigators at Memorial Sloan-Kettering Cancer Center, two new drugs — vemurafenib and ipilimumab (Yervoy™) — were found to prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer. Medical oncologist Paul Chapman and Jedd Wolchok (vemurafenib )are quoted.
Doctors are treating cancer according to the genetic aberrations found in patients’ tumors, not just where they’re found in the body, an approach that may boost the odds of survival. Medical oncologist Leonard Saltz is quoted.
